Search hospitals > Illinois > Skokie
Orchard Healthcare Research Inc.
Claim this profileSkokie, Illinois 60077
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Lymphoma
Conducts research for Solid Tumors
48 reported clinical trials
1 medical researcher
Summary
Orchard Healthcare Research Inc. is a medical facility located in Skokie, Illinois. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Lymphoma, Solid Tumors and other specialties. Orchard Healthcare Research Inc. is involved with conducting 48 clinical trials across 48 conditions. There are 1 research doctors associated with this hospital, such as Ira Oliff.Area of expertise
1Breast Cancer
Global LeaderStage III
Stage IV
HER2 negative
2Non-Small Cell Lung Cancer
Stage IV
Stage III
Stage I
Top PIs
Clinical Trials running at Orchard Healthcare Research Inc.
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Preleukemia
Myelodysplastic Syndrome
Syndrome
Acute Myeloid Leukemia
Solid Tumors
PD-L1 Negative
Programmed Death-Ligand 1 Positive
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Recruiting4 awards Phase 3
sac-TMT + Pembrolizumab
for Breast Cancer
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (sac-TMT; MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sac-TMT plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sac-TMT plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Orchard Healthcare Research Inc.?
Orchard Healthcare Research Inc. is a medical facility located in Skokie, Illinois. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Lymphoma, Solid Tumors and other specialties. Orchard Healthcare Research Inc. is involved with conducting 48 clinical trials across 48 conditions. There are 1 research doctors associated with this hospital, such as Ira Oliff.